MX2022015277A - Composiciones y metodos para la edicion de genes. - Google Patents
Composiciones y metodos para la edicion de genes.Info
- Publication number
- MX2022015277A MX2022015277A MX2022015277A MX2022015277A MX2022015277A MX 2022015277 A MX2022015277 A MX 2022015277A MX 2022015277 A MX2022015277 A MX 2022015277A MX 2022015277 A MX2022015277 A MX 2022015277A MX 2022015277 A MX2022015277 A MX 2022015277A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- gene editing
- genomes
- manipulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033397P | 2020-06-02 | 2020-06-02 | |
| US202063114850P | 2020-11-17 | 2020-11-17 | |
| US202163171698P | 2021-04-07 | 2021-04-07 | |
| PCT/US2021/035244 WO2021247570A2 (en) | 2020-06-02 | 2021-06-01 | Compositions and methods for gene editing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015277A true MX2022015277A (es) | 2023-02-13 |
Family
ID=78831704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015277A MX2022015277A (es) | 2020-06-02 | 2021-06-01 | Composiciones y metodos para la edicion de genes. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240309345A1 (enExample) |
| EP (1) | EP4158009A4 (enExample) |
| JP (1) | JP2023529611A (enExample) |
| KR (1) | KR20230031832A (enExample) |
| AU (2) | AU2021283185A1 (enExample) |
| CA (1) | CA3184884A1 (enExample) |
| GB (2) | GB2637278B (enExample) |
| IL (1) | IL298434A (enExample) |
| MX (1) | MX2022015277A (enExample) |
| WO (1) | WO2021247570A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022318664A1 (en) | 2021-07-30 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| US20240254483A1 (en) | 2021-07-30 | 2024-08-01 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
| IL311610A (en) | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
| CN119836432A (zh) * | 2022-05-01 | 2025-04-15 | 恩科洛玛生物公司 | 用于pcsk9表达的表观遗传调节的组合物和方法 |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| EP4544058A1 (en) * | 2022-06-23 | 2025-04-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of ciita expression |
| KR20250059560A (ko) * | 2022-06-23 | 2025-05-02 | 크로마 메디슨, 인크. | 후성유전학적 편집을 위한 조성물 및 방법 |
| WO2023250148A1 (en) * | 2022-06-23 | 2023-12-28 | Chroma Medicine, Inc. | Compositions and methods for epigenetic editing |
| WO2023250490A1 (en) * | 2022-06-23 | 2023-12-28 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of trac expression |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
| CA3260110A1 (en) | 2022-06-24 | 2023-12-28 | European Molecular Biology Laboratory | MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI |
| EP4554967A2 (en) | 2022-07-12 | 2025-05-21 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
| JP2025526073A (ja) * | 2022-08-11 | 2025-08-07 | エピジェニック・セラピューティクス・プライベイト・リミテッド | エピジェネティック編集標的部位のための方法およびその使用 |
| WO2024032681A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| WO2024040254A2 (en) * | 2022-08-19 | 2024-02-22 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
| WO2024044574A1 (en) * | 2022-08-23 | 2024-02-29 | The Regents Of The University Of California | Compositions and methods for reducing ionizing radiation-induced hematopoietic stem cell damage |
| JP2025531268A (ja) | 2022-09-19 | 2025-09-19 | チューン セラピューティクス インコーポレイテッド | Ｔ細胞機能を調節するための組成物、システム、および方法 |
| KR20250110209A (ko) * | 2022-09-23 | 2025-07-18 | 엔크로마 바이오, 인크. | Hbv 유전자 발현의 에피제네틱 조절을 위한 조성물 및 방법 |
| WO2024081879A1 (en) * | 2022-10-14 | 2024-04-18 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of cd247 expression |
| WO2024163683A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist) |
| WO2024163678A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods |
| JP2026506083A (ja) | 2023-02-17 | 2026-02-20 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | エピジェネティック修飾を行うための組成物および方法 |
| WO2024238321A1 (en) * | 2023-05-12 | 2024-11-21 | Mammoth Biosciences, Inc. | Compositions and methods for targeted epigenetic modification |
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ，インコーポレーテッド | Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法 |
| TW202503061A (zh) * | 2023-06-16 | 2025-01-16 | 大陸商益杰立科（上海）生物科技有限公司 | 靶向ｂ型肝炎病毒基因的表觀編輯工具 |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| EP4754248A1 (en) | 2023-07-31 | 2026-06-10 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| WO2025038494A1 (en) | 2023-08-11 | 2025-02-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation |
| WO2025059073A1 (en) | 2023-09-11 | 2025-03-20 | Tune Therapeutics, Inc. | Epigenetic editing methods and systems for differentiating stem cells |
| WO2025251019A1 (en) * | 2024-05-31 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic editing |
| WO2025260068A1 (en) | 2024-06-14 | 2025-12-18 | Tune Therapeutics, Inc. | Lipid nanoparticle formulation for delivery of nucleic acids to cells |
| WO2026015647A1 (en) | 2024-07-09 | 2026-01-15 | Tune Therapeutics, Inc. | Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1 |
| WO2026064753A1 (en) | 2024-09-23 | 2026-03-26 | Tune Therapeutics, Inc. | Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing |
| WO2026102058A1 (en) | 2024-11-06 | 2026-05-15 | Tune Therapeutics, Inc. | Methods for treating chronic hepatitis b infection and related formulations |
| WO2026161895A1 (en) | 2025-01-27 | 2026-07-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015298571B2 (en) * | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3443081A4 (en) * | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| US11286493B2 (en) * | 2016-05-27 | 2022-03-29 | The Regents Of The University Of California | Methods and compositions for targeting RNA polymerases and non-coding RNA biogenesis to specific loci |
| AU2019255789B2 (en) * | 2018-04-19 | 2025-11-20 | The Regents Of The University Of California | Compositions and methods for gene editing |
-
2021
- 2021-06-01 EP EP21818236.8A patent/EP4158009A4/en active Pending
- 2021-06-01 IL IL298434A patent/IL298434A/en unknown
- 2021-06-01 US US17/999,756 patent/US20240309345A1/en active Pending
- 2021-06-01 GB GB2506591.3A patent/GB2637278B/en active Active
- 2021-06-01 AU AU2021283185A patent/AU2021283185A1/en not_active Abandoned
- 2021-06-01 CA CA3184884A patent/CA3184884A1/en active Pending
- 2021-06-01 WO PCT/US2021/035244 patent/WO2021247570A2/en not_active Ceased
- 2021-06-01 GB GB2219607.5A patent/GB2612212B/en active Active
- 2021-06-01 KR KR1020227044336A patent/KR20230031832A/ko active Pending
- 2021-06-01 MX MX2022015277A patent/MX2022015277A/es unknown
- 2021-06-01 JP JP2022574164A patent/JP2023529611A/ja active Pending
-
2026
- 2026-05-12 AU AU2026203640A patent/AU2026203640A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021247570A2 (en) | 2021-12-09 |
| GB202506591D0 (en) | 2025-06-11 |
| AU2021283185A1 (en) | 2023-01-05 |
| KR20230031832A (ko) | 2023-03-07 |
| GB2612212A (en) | 2023-04-26 |
| JP2023529611A (ja) | 2023-07-11 |
| US20240309345A1 (en) | 2024-09-19 |
| IL298434A (en) | 2023-01-01 |
| AU2026203640A1 (en) | 2026-07-23 |
| GB2637278B (en) | 2025-11-05 |
| GB2637278A (en) | 2025-07-16 |
| GB2612212B (en) | 2025-06-18 |
| CA3184884A1 (en) | 2021-12-09 |
| EP4158009A2 (en) | 2023-04-05 |
| EP4158009A4 (en) | 2024-10-02 |
| WO2021247570A8 (en) | 2023-01-05 |
| GB202219607D0 (en) | 2023-02-08 |
| WO2021247570A3 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021247570A8 (en) | Compositions and methods for gene editing | |
| MX2025005087A (es) | Composiciones y metodos para la edicion de genes | |
| PH12021551114A1 (en) | Crispr-cas12j enzyme and system | |
| PH12021550904A1 (en) | Novel crispr/cas12f enzyme and system | |
| WO2019191341A8 (en) | Nucleic acid-based therapeutics | |
| EP4471149A3 (en) | Type v crispr-cas base editors and methods of use thereof | |
| WO2020172492A3 (en) | Bacterial membrane preparations | |
| WO2021067246A8 (en) | Deterministic barcoding for spatial omics sequencing | |
| PH12021550843A1 (en) | Nucleic acid constructs and methods of use | |
| EA202191033A1 (ru) | Программируемое редактирование оснований днк посредством слитых белков nme2cas9-дезаминаза | |
| EP4524148A3 (en) | Anti-vegf protein compositions and methods for producing the same | |
| WO2021242793A3 (en) | Nucleic acid artificial mini-proteome libraries | |
| CL2023000554A1 (es) | Proteínas diseñadas y métodos de uso de las mismas. | |
| MX2021004602A (es) | Edición del genoma por inserción no homóloga de adn dirigida utilizando una proteína de fusión retroviral integrasacas9. | |
| WO2020198174A8 (en) | Simultaneous multiplex genome editing in yeast | |
| WO2022034374A3 (en) | Improved gene editing | |
| WO2020006131A3 (en) | Nucleases for genome editing | |
| WO2023164670A3 (en) | Crispr-cas9 compositions and methods with a novel cas9 protein for genome editing and gene regulation | |
| EP3943512A4 (en) | FUSION PROTEIN TO ENHANCE GENE EDITING AND USE | |
| WO2020237066A3 (en) | Gene editing in diverse bacteria | |
| MX2020011470A (es) | Metodos de terapia genica. | |
| AU2021343526A9 (en) | Constructs and uses thereof for efficient and specific genome editing | |
| EP4499838A4 (en) | MODIFIED GENE EFFECTORS, COMPOSITIONS AND THEIR METHODS OF USE | |
| WO2021248023A3 (en) | Compositions and methods for epigenome editing | |
| CL2025002637A1 (es) | Proteínas de ingeniería y métodos de uso. |